Campath-1H in rheumatoid arthritis - An intravenous dose-ranging study

Revmatologiia

Volumn 35, Issue 3, 1996, Pages 231-240

  Isaacs, J D ^a,g   Manna, V K ^b   Rapson, N ^b   Bulpitt, K J ^c   Hazleman, B L ^a   Matteson, E L ^d   Clair, E W St ^e   Schnitzer, T J ^f   Johnston, J M ^b  

^a CAMBRIDGE UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^b GLAXOSMITHKLINE   (United Kingdom)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d MAYO CLINIC   (United States)

^e DUKE UNIVERSITY MEDICAL CENTER   (United States)

^f RUSH UNIVERSITY MEDICAL CENTER   (United States)

^g Rheumatology and Rehabilitation Research Unit   (United Kingdom)

Author keywords

Antiglobulin response; CAMPATH 1H; Immunotherapy; Monoclonal antibody; Rheumatoid arthritis

Indexed keywords

ALEMTUZUMAB; MONOCLONAL ANTIBODY;

ACUTE KIDNEY FAILURE; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; DISEASE ACTIVITY; DYSPNEA; FEMALE; HEMOLYTIC UREMIC SYNDROME; HUMAN; HYPOTENSION; INFLUENZA; INTRAVENOUS DRUG ADMINISTRATION; LYMPHOCYTOPENIA; MALE; MYALGIA; OPPORTUNISTIC INFECTION; PRIORITY JOURNAL; RASH; RHEUMATOID ARTHRITIS;

ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; ARTHRITIS, RHEUMATOID; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; FEMALE; HUMANS; INJECTIONS, INTRAVENOUS; JOINTS; LYMPHOCYTE COUNT; MALE; MIDDLE AGED; PAIN MEASUREMENT; TIME FACTORS;

EID: 0029875268     PISSN: 13100505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Waldmann H. Manipulation of T cell responses with monoclonal antibodies. Annu Rev Immunol 1989;7:407-44.
2. Isaacs JD. Monoclonal antibodies in rheumatology. In: Ritter M, Ladyman P, eds. Monoclonal antibodies: production, engineering and clinical application. Cambridge: Cambridge University Press, 1985:403-28.
3. Herzog C, Walker C, Muller W et al. Anti-CD4 antibody treatment of patients with rheumatoid arthritis: I. Effect on clinical course and circulating T cells. J Autoimmun 1989;2:627-42.
4. Reiter C, Kakarand B, Rieber EP, Schattenkirchner M, Riethmuller G, Kruger K. Treatment of rheumatoid arthritis with monoclonal anti-CD4 antibody M-T151. Clinical results and immuno-pharmacologic effects in an open study, including repeated administration. Arthritis Rheum 1991;34:525-36.
5. Horneff G, Burmester GR, Emmrich F, Kalden JR. Treatment of rheumatoid arthritis with an anti-CD4 monoclonal antibody. Arthritis Rheum 1991;34:129-40.
6. Goldberg D, Morel P, Chatenoud L et al. Immunological effects of high dose administration of anti-CD4 antibody in rheumatoid arthritis patients. J Autoimmun 1991; 4:617-30.
7. Moreland LW, Bucy RP, Tilden A et al. Use of a chimeric monoclonal anti-CD4 antibody in patients with refractory rheumatoid arthritis. Arthritis Rheum 1993; 36:307-18.
8. Moreland LW, Pratt PW, Mayes MD et al. Double-blind, placebo-controlled multicenter trial using chimeric monoclonal anti-CD4 antibody, CM-T412 in rheumatoid arthritis patients receiving methotrexate. Arthritis Rheum 1995;38:1581-8.
9. Van der Lubbe PA, Dijkmans BAC, Markusse HM, Nassander U, Breedveld FC. A randomized, double-blind, placebo-controlled study of CD4 monoclonal antibody therapy in early rheumatoid arthritis. Arthritis Rheum 1995;38:1097-106.
10. Cobbold SP, Qin S, Leong LYW, Martin G, Waldmann H. Reprogramming the immune system for peripheral tolerance with CD4 and CD8 monoclonal antibodies. Immunol Rev 1992;129:165-201.
11. Cobbold SP, Martin G, Waldmann H. The induction of skin graft tolerance in major histocompatibility complex-mismatched or primed recipients: primed T cells can be tolerized in the periphery with anti-CD4 and anti-CD8 antibodies. Eur J Immunol 1990;20:2747-55.
12. Hale G, Xia M-Q, Tighe HP, Dyer MJS, Waldmann H. The Campath-1 antigen (CDw52). Tissue Antigens 1990;35:118-27.
13. Hale G, Bright S, Chumbley G et al. Removal of T cells from bone marrow for transplantation: a monoclonal anti-lymphocyte antibody that fixes human complement. Blood 1983;62:873-82.
14. Riechmann L, Clark M, Waldmann H, Winter G. Reshaping human antibodies for therapy. Nature 1988;332:323-7.
15. Isaacs JD, Watts RA, Hazleman BL et al. Humanised monoclonal antibody therapy for rheumatoid arthritis. Lancet 1992;340:748-52.
16. Arnett FC, Edworthy SM, Bloch DA et al. The American Rheumatism Association revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
17. Weinblatt ME, Maddison PJ, Bulpitt KJ et al. CAMPATH-1H, a humanized monoclonal antibody, in refractory rheumatoid arthritis: An intravenous dose-escalation study. Arthritis Rheum 1995;38:1589-94.
18. Matteson EL, Yocum DE, St Clair EW et al. Treatment of active refractory rheumatoid arthritis with humanized monoclonal antibody CAMPATH-1H administered by daily sub-cutaneous injection. Arthritis Rheum 1995;38:1187-93.
19. Cobbold SP, Rebello PRUB, Davies HFfs, Friend PJ, Clark MR. A simple method for measuring patient anti-globulin responses against isotypic or idiotypic determinants. J Immunol Methods 1990;127:19-24.
20. Paulus HE, Egger MJ, Ward JR, Williams HJ and the Cooperative Systematic Studies of the Rheumatic Diseases Group. Analysis of improvement in individual rheumatoid arthritis patients treated with disease-modifying antirheumatic drugs, based on the findings in patients treated with placebo. Arthritis Rheum 1990;33:477-84.
21. Moreland LW, Pratt PW, Bucy RP, Jackson BS, Feldman JW, Koopman WJ. Treatment of refractory rheumatoid arthritis with a chimeric anti-CD4 monoclonal antibody. Longterm follow-up of CD4+ T-cell counts. Arthritis Rheum 1994;37:834-8.
22. Watts RA, Isaacs JD, Hale G, Hazleman BL, Waldmann H. Peripheral blood lymphocyte subsets after CAMPATH-1H therapy in rheumatoid arthritis - a 3 year follow-up. Arthritis Rheum 1994;37:S338.
23. Fauci AS. CD4+ T-lymphopenia without HIV infection - no lights, no camera, just facts. N Engl J Med 1993;328:429-31.
24. Jendro MC, Ganten T, Matteson EL, Weyand CM, Goronzy JJ. Emergence of oligoclonal T cell populations following therapeutic T cell depletion in rheumatoid arthritis. Arthritis Rheum 1995;38:1242-51.
25. Chatenoud L, Bach J-F. OKT3 in allogeneic transplantation: clinical efficacy, mode of action, and side effects. In: Burlingham WJ, ed. A critical analysis of monoclonal antibody therapy in transplantation. Boca Raton, FL: CRC Press, 1992.
26. Moreau T, Coles A, Wing MG, Isaacs J, Hale G, Waldmann H, Compston A. Transient increase in symptoms associated with cytokine release in patients with multiple sclerosis. Brain 1996;119:225-37.
27. Isaacs JD, Waldmann H. Helplessness as a strategy for avoiding antiglobulin responses to therapeutic antibodies. Ther Immunol 1994;1:303-12.
28. Strand V, Lipsky PE, Cannon GW et al. Effects of administration of an anti-CD5 plus immunoconjugate in rheumatoid arthritis. Results of two phase II studies. Arthritis Rheum 1993;36:620-30.
29. Cobbold SP, Barel D, Waldmann H. Manipulating the immune system with monoclonal antibodies. Mouse models for immunotherapy. In: Feldmann M, Lamb J, Owen MJ, eds. T-cells. New York: Wiley, 1989.
30. Ruderman EM, Weinblatt ME, Thurmond LM, Pinkus GS, Gravalesse EM. Synovial tissue response to treatment with CAMPATH-1H. Arthritis Rheum 1995;38:254-8.
31. Choy EHS, Pitzalis C, Bijl JA, Kingsley GH, Panayi GS. The amount of anti-CD4 monoclonal antibody (mAb) entering the rheumatoid (RA) joint may determine clinical efficacy. Arthritis Rheum 1993;36:S39.
32. Lockwood CM, Thiru S, Isaacs JD, Hale G, Waldmann H. Long-term remission of intractable systemic vasculitis with monoclonal antibody therapy. Lancet 1993;341: 1620-2.
33. Elliott MJ, Maini RN, Feldmann M et al. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor a (cA2) versus placebo in rheumatoid arthritis. Lancet 1994;344:1105-10.
34. Williams RO, Mason LJ, Feldmann M, Maini RN. Synergy between anti-CD4 and anti-tumor necrosis factor in the amelioration of established collagen-induced arthritis. Proc Natl Acad Sci USA 1994;91:2762-6.
35. Qin S, Cobbold SP, Pope H et al. 'Infectious' transplantation tolerance. Science 1993;259:974-7.